Triple-negative breast cancer (TNBC) has high rates of recurrence despite chemotherapy and immune checkpoint blockade (ICB). Tumor-associated macrophages (TAMs) can either suppress or support antitumor immunity, but the mechanisms governing these states and therapeutic targets remain unclear. Here, integrating public s...
Alex J. Smith, Z. Schrank, Nan Guan et al.· Cancer immunology research· 0 citations
Inhibiting pan-RAS(on) RAS-GTP with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.
Michael P. East, J. Olivares-Quintero, D. Okumu et al.· bioRxiv· 0 citations
BACKGROUND Despite therapeutic advances in early-stage triple-negative breast cancer (TNBC), residual disease (RD) following neoadjuvant therapy remains a key predictor of a worse prognosis and obstacle to improving patient outcomes. METHODS To better characterize RD and identify survival-associated features, we perfor...
P. D. Rädler, B. Felsheim, A. Fernández-Martínez et al.· Journal of Clinical Investig...· 0 citations
Comparing of multiple computational approaches, including XGBoost, random forests, and support vector regression, showed that all methods successfully predicted survival outcomes, with Elastic Net offering the best performance and interpretability.
Matthew D. Sutcliffe, K. Mott, Tulay Yilmaz-Swenson et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
